Ischemic heart disease and ankylosing spondylitis—assessing the role of inflammation

被引:0
|
作者
Michal Vinker Shuster
Omer Gendelman
Shmuel Tiosano
Doron Comaneshter
Arnon D. Cohen
Howard Amital
机构
[1] The Hebrew University of Jerusalem,Department of Medicine ‘B’, Zabludowicz Center for Autoimmune Diseases
[2] Hadassah Hebrew University Medical Center,Sackler Faculty of Medicine
[3] Sheba Medical Center,Chief Physician’s Office
[4] Tel-Aviv University,Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences
[5] Clalit Health Services,undefined
[6] Ben-Gurion University of the Negev,undefined
来源
Clinical Rheumatology | 2018年 / 37卷
关键词
Ankylosing spondylitis; Autoimmunity; Ischemic heart disease; Risk factors;
D O I
暂无
中图分类号
学科分类号
摘要
To assess the association of ankylosing spondylitis (AS) and ischemic heart disease (IHD) compared to traditional cardiovascular (CV) risk factors. Primary care and hospital records of patients with AS were analyzed, using the largest health maintenance organization in Israel, the “Clalit” Health Services data. These patients were compared with age- and gender-matched controls regarding the proportion of IHD in a cross-sectional study. Parameters including socioeconomic status, body mass index (BMI), smoking habits, and coexistent medical conditions hypertension, hyperlipidemia, and diabetes mellitus (DM) - as well as the use of NSAIDs and anti-TNFs were also assessed. The study included 4076 AS patients compared to 20,290 age- and gender-matched controls without AS. The proportion of IHD was higher among AS patients as compared to controls (14.1 vs. 6.36%, respectively, p < 0.01) and patients treated with anti-TNFs had a lower risk for IHD compared to non-anti-TNF users. The proportion of hypertension, hyperlipidemia, DM, and smoking was also higher among AS patients. However, in multivariate analyses following adjustment to these risk factors, AS was not found to be associated with IHD nor anti-TNF therapy to be a protective factor. Patients with AS have more traditional CV risk factors, thus are in a higher risk for IHD. AS itself was not shown to be independently associated with IHD. These findings emphasize the multifactorial process leading to increased proportion of IHD among AS patients and the need for a stringent control of traditional risk factors in these patients.
引用
收藏
页码:1053 / 1058
页数:5
相关论文
共 50 条
  • [21] Inflammation and embolization in ischemic heart disease
    Topol, EJ
    JOURNAL OF INVASIVE CARDIOLOGY, 2000, 12 : 2B - 7B
  • [22] Curbing Inflammation in the Ischemic Heart Disease
    Evora, Paulo Roberto B.
    Nather, Julio
    Tubino, Paulo Victor
    Albuquerque, Agnes Afrodite S.
    Celotto, Andrea Carla
    Rodrigues, Alfredo J.
    INTERNATIONAL JOURNAL OF INFLAMMATION, 2013, 2013
  • [23] The Role of MicroRNAS in Ankylosing Spondylitis
    Li, Zheng
    Wong, Sunny H.
    Shen, Jianxiong
    Chan, Matthew T. V.
    Wu, William Ka Kei
    MEDICINE, 2016, 95 (14)
  • [24] Role of the Pharmacist in Ankylosing Spondylitis
    Davis, Sarah
    Graves, Katy
    Kyle, Jeffrey A.
    US PHARMACIST, 2024, 49 (07)
  • [25] THE ROLE OF ANKH IN ANKYLOSING SPONDYLITIS
    Timms, A. E.
    Zhang, Y.
    Bradbury, L.
    Wordsworth, P.
    Brown, M. A.
    RHEUMATOLOGY, 2003, 42 : 65 - 65
  • [26] The role of etanercept in ankylosing spondylitis
    Davis, JC
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (06) : S111 - S115
  • [27] The role of B*60 in disease expression of ankylosing spondylitis.
    Calin, A
    Brophy, S
    Kennedy, LG
    Brown, M
    Wordsworth, P
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1083 - 1083
  • [28] Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations
    Song, I. H.
    Rudwaleit, M.
    Listing, J.
    Sieper, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (11) : 1701 - 1707
  • [29] Cardiovascular risk in patients with ankylosing spondylitis: the role of systemic inflammation and endothelial dysfunction
    Poddubnyy, D. A.
    Rebrov, A. P.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2008, 4 (05) : 71 - 76
  • [30] ANKYLOSING SPONDYLITIS AND HEMOLYTIC DISEASE
    KOSTINAS, JE
    WETZEL, RA
    CANTOW, EF
    PELLECCH.JA
    SOUTHERN MEDICAL JOURNAL, 1968, 61 (01) : 43 - &